Rallybio Corporation (RLYB) vs Telomir Pharmaceuticals, Inc. (TELO)

Rallybio Corporation and Telomir Pharmaceuticals, Inc. are both Biotechnology companies. Rallybio Corporation and Telomir Pharmaceuticals, Inc. are of similar size ($88.2M and $83.2M). Telomir Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.1×. Across the 10 metrics below, Rallybio Corporation leads on 8 and Telomir Pharmaceuticals, Inc. on 2.

Valuation

Metric RLYB TELO Biotechnology median
P/E 2.06 n/m 7.88
P/S 110.39 n/m 11.47
P/B 1.00 14.75 2.52
Price to free cash flow 3.55 n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.18 n/m 10.73
Earnings yield 48.49% (74.59%) (28.84%)
Free cash flow yield 28.17% (6.62%) (23.03%)

Profitability

Metric RLYB TELO Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 64.86% (1,885.50%) (57.72%)
Return on assets 61.12% (1,678.31%) (49.22%)
Return on invested capital (1,052.03%) 0.00% 0.00%

Growth

Metric RLYB TELO Biotechnology median
Revenue growth (TTM) 1.18% — 5.64%
EPS growth (last fiscal year) 85.06% 41.07% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric RLYB TELO Biotechnology median
Debt to equity 0.00 0.03 0.00
Current ratio 27.26 16.14 4.73
Net debt to EBITDA 1.63 0.69 0.96

Dividend

Metric RLYB TELO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric RLYB TELO Biotechnology median
Market cap 88.21m 83.22m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack